PsychoGenics 5-HT1A/B receptor agonist eltoprazine shows efficacry in ADHD « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

PsychoGenics 5-HT1A/B receptor agonist eltoprazine shows efficacry in ADHD

Posted on June 2, 2008 by crimsoncanary

Phase IIa data released by PsychoGenics show its lead partial 5-HT1A – 5-HT1B receptor agonist eltoprazine to demonstrate efficacy in adults with attention deficit hyperactivity disorder (ADHD). The compound reduced the ADHD-RS-IV total score of 42% from baseline compared to placebo (p<0.051).

Filed under: gpcr | Tagged: 5-HT1A, 5-HT1B, 5HT1A, 5HT1B, agonist, eltoprazine, PsychoGenics

« FDA Advisory committee recommends against expanded use of Fentora NeurogesX submit IND for liquid formulation of Capsaicin, NGX-1998 »

Leave a Reply